Viking shares soared Tuesday with “stellar” results from trials of its weight-loss shot, dragging down shares of rivals Eli Lilly (LLY) and Novo (NVO). The study examined weekly and monthly doses of Viking Therapeutics (VKTX) injection, VK2735, for three months as a means of maintaining weight loss with weekly dosing. Patients in the biweekly program maintained up to 97%… Copyright ©2026 Investor’s Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8
